[go: up one dir, main page]

MXPA03002991A - Formulaciones medicinales en aerosol. - Google Patents

Formulaciones medicinales en aerosol.

Info

Publication number
MXPA03002991A
MXPA03002991A MXPA03002991A MXPA03002991A MXPA03002991A MX PA03002991 A MXPA03002991 A MX PA03002991A MX PA03002991 A MXPA03002991 A MX PA03002991A MX PA03002991 A MXPA03002991 A MX PA03002991A MX PA03002991 A MXPA03002991 A MX PA03002991A
Authority
MX
Mexico
Prior art keywords
aerosol formulations
bulking agents
medicinal aerosol
less
propyliodone
Prior art date
Application number
MXPA03002991A
Other languages
English (en)
Inventor
Philip A Jinks
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0024711.4A external-priority patent/GB0024711D0/en
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of MXPA03002991A publication Critical patent/MXPA03002991A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

El uso de agentes de abultamiento o agrupacion en particulas que tengan un diametro de masa medio extremadamente pequeno menor de 1 micron, preferiblemente menor de 300nm, en formulaciones farmaceuticas en aerosol que comprenden una suspension de particulas de farmaco en un propelente. Ejemplos de agente de abultamiento o agrupacion incluyen ael acido ascorbico, sacaridos, polisacaridos, aminoacidos, sales organicas e inorganicas, urea y propiliodona.
MXPA03002991A 2000-10-09 2001-10-01 Formulaciones medicinales en aerosol. MXPA03002991A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0024711.4A GB0024711D0 (en) 2000-10-09 2000-10-09 Medicinal aerosol formulations
GBGB0122512.7A GB0122512D0 (en) 2000-10-09 2001-09-18 Medical aerosol formations
PCT/US2001/030575 WO2002030394A2 (en) 2000-10-09 2001-10-01 Medicinal aerosol formulations

Publications (1)

Publication Number Publication Date
MXPA03002991A true MXPA03002991A (es) 2004-05-05

Family

ID=26245133

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03002991A MXPA03002991A (es) 2000-10-09 2001-10-01 Formulaciones medicinales en aerosol.

Country Status (17)

Country Link
EP (1) EP1324749B1 (es)
JP (1) JP5021149B2 (es)
CN (1) CN1635870A (es)
AR (1) AR030862A1 (es)
AT (1) ATE320242T1 (es)
AU (2) AU1131102A (es)
CA (1) CA2425035A1 (es)
CZ (1) CZ2003983A3 (es)
DE (1) DE60118021T2 (es)
ES (1) ES2260299T3 (es)
HU (1) HUP0302311A3 (es)
IL (1) IL155088A0 (es)
MX (1) MXPA03002991A (es)
NO (1) NO20031597L (es)
NZ (1) NZ525054A (es)
PL (1) PL199420B1 (es)
WO (1) WO2002030394A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1337239B2 (en) 2000-11-30 2015-11-25 Vectura Limited Particles for use in a pharmaceutical composition
DK1337240T4 (en) 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
JP2005536538A (ja) * 2002-08-23 2005-12-02 シェーリング　コーポレイション 薬学的組成物
US7109247B2 (en) * 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
JP2006527237A (ja) 2003-06-13 2006-11-30 アルタナ　ファルマ　アクチエンゲゼルシャフト ホルモテロールと及びシクレソニドの組合せ物
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
PL1670482T5 (pl) 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
CA2581999C (en) * 2004-10-12 2013-04-23 Generics (Uk) Limited Preparation of suspension aerosol formulations
EP1949891A1 (en) * 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
NZ556709A (en) 2005-02-10 2009-09-25 Glaxo Group Ltd Process for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
CN100435784C (zh) * 2005-07-25 2008-11-26 管晓虹 含有和包封中药成分的无机盐纳米粒子的制备方法
CN100335038C (zh) * 2005-07-25 2007-09-05 江桥 含有生物活性物质和中药成分包封的无机盐纳米粒子的制备方法
DE102006040535A1 (de) * 2006-08-30 2008-03-13 Beiersdorf Ag Aerosolzubereitung umfassend Peloide
CN101380309B (zh) * 2007-09-03 2012-05-09 李浩莹 一种定量吸入气雾剂及其制备方法
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
JP2014519519A (ja) 2011-06-15 2014-08-14 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規３，４，４ａ，１０ｂ−テトラヒドロ−１Ｈ−チオピラノ［４，３−ｃ］イソキノリン化合物
AR086915A1 (es) 2011-06-17 2014-01-29 Nycomed Gmbh Derivados de ftalazinona-pirrolopirimidinacarboxamida y composiciones farmaceuticas que los contiene
WO2018069210A1 (en) 2016-10-10 2018-04-19 Takeda Gmbh Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4
CN109464429B (zh) * 2018-12-13 2021-04-27 上海方予健康医药科技有限公司 一种吸入压力定量气雾剂药物组合物及其制备方法
CN110755414A (zh) * 2019-11-12 2020-02-07 南京华盖制药有限公司 一种酒石酸阿福特罗气雾剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
EP0810853B1 (en) * 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions

Also Published As

Publication number Publication date
JP5021149B2 (ja) 2012-09-05
WO2002030394A3 (en) 2003-01-30
PL361135A1 (en) 2004-09-20
PL199420B1 (pl) 2008-09-30
NZ525054A (en) 2004-11-26
ATE320242T1 (de) 2006-04-15
NO20031597D0 (no) 2003-04-08
NO20031597L (no) 2003-05-30
WO2002030394A2 (en) 2002-04-18
CZ2003983A3 (cs) 2003-09-17
CN1635870A (zh) 2005-07-06
HUP0302311A2 (hu) 2003-10-28
DE60118021T2 (de) 2006-10-26
HUP0302311A3 (en) 2006-07-28
CA2425035A1 (en) 2002-04-18
AR030862A1 (es) 2003-09-03
IL155088A0 (en) 2003-10-31
AU1131102A (en) 2002-04-22
AU2002211311B2 (en) 2006-08-31
JP2004510808A (ja) 2004-04-08
EP1324749A2 (en) 2003-07-09
DE60118021D1 (de) 2006-05-11
ES2260299T3 (es) 2006-11-01
EP1324749B1 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
MXPA03002991A (es) Formulaciones medicinales en aerosol.
WO2004060351A3 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
JO2381B1 (en) Formulation containing anticholinergic drug for the treatment of chronic obstructive pulmonary disease
ES2193726T3 (es) Formulaciones de aerosol medicinales.
IL161290A0 (en) Stable composition comprising particles in a frozen aqueous matrix
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
ES2136883T3 (es) Nueva formulacion mejorada de aminoglucosido para administracion en forma de aerosol.
AR018252A1 (es) Forma de dosificacion farmaceutica en particulas solidas adecuada para suministro oral.
DE69835162D1 (de) Geschmacksmaskierte pharmazeutische zusammensetzungen
NZ334149A (en) Pharmaceutical aerosol composition containing an active material, a propellant containing a hydrofluoroalkane and a cosolvent and a low volatility component
DE60121570D1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
WO2002098390A3 (en) Delivery of aerosols containing small particles through an inhalation route
HUP0000520A2 (hu) Új vizes gyógyszerkészítmények hajtógázmentes aeroszolokhoz
CA2311450A1 (en) Pharmaceutical aerosol compositions
AU2155199A (en) Microparticles for drug delivery across mucosa and the blood-brain barrier
DE69915733D1 (de) Kosmetische oder pharmazeutische Zusammensetzung in Form eines Feststoffs, welche verformt werden kann
YU8701A (sh) Nova oralna kompozicija
AU2517792A (en) Pharmaceutical aerosol preparation and its use for treatment and prophylaxis of viral diseases
IT1317720B1 (it) Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
JO2325B1 (en) A pharmaceutical composition with a flavoring taste and a process to prepare it
DE59811768D1 (de) Pharmazeutische kombinationspräparate enthaltend erythropoietin und modifizierte hämoglobine
EP2612703A3 (en) Particulate materials
WO1996040074A3 (en) Device for releasing aggregation-stabilized, biologically active agent
CA2305359A1 (en) Drug delivery system
WO2001082868A3 (en) A medicinal aerosol formulation